

Appl. No. 09/488,728
Amdt. and Reply dated August 4, 2005
Resp. to OA, dated February 24, 2005

3. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-12 (*Cancelled*)

13. (*Previously presented*) A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:

- (a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
- (b) a protein comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) that binds IL-17; and
- (c) a fragment of (a) that binds IL-17.

14-16 (*Cancelled*)

17. (*Previously presented*) A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:

- (a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
- (b) a protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) that binds IL-17; and
- (c) a fragment of (a) that binds IL-17.

18. (*Cancelled*)

19. (*Previously presented*) A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.

20. (*Previously presented*) A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier,

Appl. No. 09/488,728
Amdt. and Reply dated August 4, 2005
Resp. to OA, dated February 24, 2005

wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.

21. *(Previously presented)* A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.

22. *(Previously presented)* The method according to claim 13, wherein the soluble IL-17R protein further comprises an Fc domain.

23. *(Previously presented)* The method according to claim 13, wherein the soluble IL-17R protein further comprises an oligomerizing domain.

24. *(Previously presented)* A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.

25. *(Previously presented)* A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.

26. *(Previously presented)* A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.

27. *(Previously presented)* The method according to claim 17, wherein the soluble IL-17R protein further comprises an Fc domain.

Appl. No. 09/488,728
Amdt. and Reply dated August 4, 2005
Resp. to OA, dated February 24, 2005

28. *(Previously presented)* The method according to claim 17, wherein the soluble IL-17R protein further comprises an oligomerizing domain.